Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.

PloS one - 3 Sept 2010

Cheung Chun Hei Antonio, Wu Su-Ying, Lee Tian-Ren, Chang Chi-Yen, Wu Jian-Sung, Hsieh Hsing-Pang, Chang Jang-Yang

Abstract excerpt

BACKGROUND: Anti-mitotic compounds (microtubule de-stabilizers) such as vincristine and vinblastine have been shown clinically successful in treating various cancers. However, development of drug-resistance cells limits their efficacies in clinical situations. Therefore, experiments were performed to determine possible drug resistance mechanisms related to the application of anti-mitotic cancer therapy. PRINCIPAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to HeLa Cells

Share to Mutation

Share to Neoplasms

Share to Protein Isoforms

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 20838440
DOI: 10.1371/journal.pone.0012564
PMCID: PMC2933234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.PMID 20838440Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Microtubules: A dynamic target in cancer therapySemantic proximity Read ↗

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.Semantic proximity Read ↗

KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubulesSemantic proximity Read ↗

New Microtubule / Tubulin-Targeted Anticancer Drugs and Novel Chemotherapeutic StrategiesSemantic proximity Read ↗

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.Semantic proximity Read ↗

The role of beta-tubulin isotypes in resistance to antimitotic drugs.Semantic proximity Read ↗

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cellsSemantic proximity Read ↗

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.Semantic proximity Read ↗

Targeting Microtubules for Cancer ChemotherapySemantic proximity Read ↗

Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.